Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775365 | 0.89 | SLC6A2 (0.41) | SIRT2MAPTKMT2ACNR2ALDH1A1 | |
| SCHEMBL29896410 | 0.83 | ALDH1A1 (0.50) | SIRT2MAPTKMT2ACNR2ALDH1A1 | |
| SCHEMBL1466280 | 0.83 | ALDH1A1 (0.50) | SIRT2MAPTKMT2ACNR2ALDH1A1 | |
| SCHEMBL5775440 | 0.83 | KDM1A (0.45) | ADAM17MAPTKMT2AALDH1A1 | |
| SCHEMBL5773359 | 0.83 | HTT (0.53) | MAPTKMT2AALDH1A1 | |
| SCHEMBL5774924 | 0.82 | MAPT (0.45) | MAPTKMT2AALDH1A1 | |
| SCHEMBL7308745 | 0.81 | AR (0.41) | SIRT2MAPTKMT2AALDH1A1 | |
| SCHEMBL7308476 | 0.80 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL7308514 | 0.79 | GAA (0.51) | ABCB1MAPTKMT2AALDH1A1 | |
| SCHEMBL7306658 | 0.79 | PDPK1 (0.42) | SIRT2MAPTKMT2ACNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409485-B1 | IMMUNOMODULATING COMPOUNDS | ACTIVE BIOTECH AB (SE) | 2006-04-26 | — | — | EP | claimed |
| US-6642249-B2 | 3-Oxo-pyrazolo(4,3-c) -quinolin-2-yl, -thiochroman-2-yl, or -chromen-2-yl derivatives; CD80 antagonists | ACTIVE BIOTECH AB (SE) | 2003-11-04 | — | — | US | claimed |
| US-20030022913-A1 | Novel immunomodulating compounds | ACTIVE BIOTECH AB (SE) | 2003-01-30 | — | — | US | claimed |
| EP-1409485-B1 | IMMUNOMODULATING COMPOUNDS | ACTIVE BIOTECH AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| US-6642249-B2 | 3-Oxo-pyrazolo(4,3-c) -quinolin-2-yl, -thiochroman-2-yl, or -chromen-2-yl derivatives; CD80 antagonists | ACTIVE BIOTECH AB (SE) | 2003-11-04 | — | — | US | disclosed |
| US-20030022913-A1 | Novel immunomodulating compounds | ACTIVE BIOTECH AB (SE) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022913-A1 | Novel immunomodulating compounds | CD40, ICOS, CD40LG | PPARD 427/4885PPARA 811/4885LDHA 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.